Beta Bionics, Inc. (BBNX) Stock Price & Analysis
Beta Bionics, Inc. (BBNX) rose 3.75% to USD 14.39 as of June 10, 2026 at 06:50 UTC, according to Nexqual real-time market data.
BBNX last closed at USD 13.87; the session ranged USD 13.82–14.88 on volume of 880,778 shares. Market capitalization is $641.24M, with a 52-week range of USD 8.8–32.71 (NGM). Source: Nexqual, June 10, 2026 at 06:50 UTC.
Key Statistics (as of June 10, 2026 at 06:50 UTC)
| Price | USD 14.39 |
|---|---|
| Change | ▲ 3.75% (up) |
| Previous Close | USD 13.87 |
| Open | USD 14.05 |
| Day Range | USD 13.82 – 14.88 |
| 52-Week Range | USD 8.8 – 32.71 |
| Volume | 880,778 shares |
| Market Cap | $641.24M |
| Exchange | NGM |
Technical Analysis (BBNX)
Nexqual's technical model rates BBNX "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 06:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.92 (neutral) |
| vs SMA50 | Above (USD 10.96) |
| MACD | 0.82 (positive) |
Analyst Ratings (BBNX)
Wall Street analysts rate BBNX "Buy" based on 11 analysts, with a mean price target of USD 19.18 (range USD 13–32), per Nexqual as of June 10, 2026 at 06:50 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 19.18 |
| High Target | USD 32 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 8 / 3 / 0 |
Earnings (BBNX)
| Next Earnings Date | 2026-07-21 |
|---|---|
| EPS Estimate | USD -0.55 |
| Revenue Estimate | $31.55M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.36 vs est -0.45 ▲ beat |
| 2025-12-31 | USD -0.19 vs est -0.38 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.41 ▲ beat |
| 2025-06-30 | USD -0.27 vs est -0.47 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Financials & Fundamentals (BBNX)
| Total Revenue | $110.24M |
|---|---|
| Revenue Growth (YoY) | +56.60% |
| Gross Margin | +57.15% |
| Operating Margin | -87.86% |
| Profit Margin | -60.27% |
| ROE | -22.71% |
| Debt / Equity | 2.55 |
| Current Ratio | 10.69 |
| Total Cash | $199.52M |
| Total Debt | $6.91M |
| Free Cash Flow | $-44.06M |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Financial Health Score (BBNX)
Nexqual rates Beta Bionics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 06:50 UTC.
| Growth | Strong — Revenue +54% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 57%, operating -88% |
| Balance Sheet | Strong — $200M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$44M, burning cash |
| Efficiency | Critical — ROE -23%, ROA -15.0% |
Ownership (BBNX)
| Insider Ownership | +1.10% |
|---|---|
| Institutional Ownership | +112.60% |
| Shares Outstanding | 44.56M |
| Float | 25.34M |
| Short % of Float | +11.73% |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Leadership (BBNX)
Beta Bionics, Inc. is led by Sean T. Saint PE (age 49), President, CEO & Director, per Nexqual as of June 10, 2026 at 06:50 UTC.
| President, CEO & Director | Sean T. Saint PE (age 49) |
|---|---|
| CFO, Treasurer & Secretary | Stephen H. Feider (age 35) |
| Chief Product Officer | Mike Mensinger (age 47) |
| Vice President of Operations | David Henderson |
Major Backers & Investors (BBNX)
Notable institutional backers of Beta Bionics, Inc. include Eventide Asset Management LLC, MUTUAL FUND SERIES TRUST-Eventide Gilead Fund, Soleus Capital Management, L.P., according to Nexqual as of June 10, 2026 at 06:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eventide Asset Management LLC | 13.34% |
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 13.03% |
| Soleus Capital Management, L.P. | 9.77% |
| Morgan Stanley | 9.49% |
| Sands Capital Alternatives, LLC | 8.32% |
| Farallon Capital Management LLC | 8.1% |
| Point72 Asset Management, L.P. | 5.67% |
| Vestal Point Capital, LP | 4.96% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.5% |
| Vanguard Group | 7.66% |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
From Beta Bionics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
- It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
- The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
- It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 19.92 | ▲ 2.68% |
| CBLL | CeriBell, Inc. | USD 18.5 | ▲ 1.37% |
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
| SION | Sionna Therapeutics, Inc. | USD 33.69 | ▼ 4.75% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:50 UTC. This page is informational and not investment advice.